Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+CD25+ T regulatory cell activities in lung cancer

Cancer Research

Volumn 65, Issue 12, 2005, Pages 5211-5220

  Sharma, Sherven ^a,b   Yang, Seok Chul ^a,b   Zhu, Li ^a,b   Reckamp, Karen ^a,b   Gardner, Brian ^a   Baratelli, Felicita ^a   Huang, Min ^a,b   Batra, Raj K ^a,b   Dubinett, Steven M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; CYCLOOXYGENASE 2; GAMMA INTERFERON; INTERLEUKIN 2 RECEPTOR ALPHA; PROSTAGLANDIN E2; PROSTANOID E2 RECEPTOR; PROSTANOID E4 RECEPTOR; PROSTANOID RECEPTOR; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVITY; CELL TRANSFER; CELLULAR IMMUNITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; GENE EXPRESSION; IN VIVO STUDY; LUNG CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TUMOR IMMUNITY;

ANIMALS; CARCINOMA, LEWIS LUNG; CD4-POSITIVE T-LYMPHOCYTES; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; DNA-BINDING PROTEINS; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RECEPTORS, INTERLEUKIN-2; RECEPTORS, PROSTAGLANDIN E; TRANSFECTION;

EID: 20444464066     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0141     Document Type: Article

References (52)

1. Soslow RA, Dannenberg AJ, Rush D, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 2000;89:2637-45.
2. Huang M, Stolina M, Sharma S, et al. Non-small cell lung cancer cydooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res 1998;58: 1208-16.
3. Hida T, Yatabe Y, Achiwa H, et al. Increased expression of cycloxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998;58:3761-4.
4. Riedl K, Krysan K, Pold M, et al. Multifaceted roles of cyclooxygenase-2 in lung cancer. Drug Resist Updat 2004;7:169-84.
5. Dannenberg AJ, Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 2003;4:431-6.
6. Tsujii M, Dubois R. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase-2. Cell 1995;83:493-501.
7. Krysan K, Merchant FH, Zhu L, et al. COX-2-dependent stabilization of survivin in non-small cell lung cancer. FASEB J 2004;18:206-8.
8. Pold M, Zhu LX, Sharma S, et al. Cyclooxygenase-2-dependent expression of angiogenic CXC chemokines ENA-78/CXC ligand (CXCL) 5 and interleukin-8/CXCL8 in human non-small cell lung cancer. Cancer Res 2004;64:1853-60.
9. 2, a survival factor for tumor and associated vasculature. Cancer Res 2004;64:279-85.
10. Stolina M, Sharma S, Lin Y, et al. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 2000;164:361-70.
11. Dohadwala M, Luo J, Zhu L, et al. Non small cell lung cancer cylooxygenase-2-dependent invasion is mediated by CD44. J Biol Chem 2001;276:20809-12.
12. 2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion. J Biol Chem 2002;277:50828-33.
13. Tsujii M, Kawano S, DuBois R. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A 1997; 94:3336-40.
14. Sharma S, Stolina M, Yang SC, et al. Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clin Cancer Res 2003;9:961-8.
15. Sogn JA. Tumor immunology: the glass is half full. Immunity 1998;9:757-63.
16. Batra RK, Lin Y, Sharma S, et al. Non-small cell lung cancer-derived soluble mediators enhance apoptosis in activated T lymphocytes through an IκB kinase-dependent mechanism. Cancer Res 2003;63:642-6.
17. Yoshino I, Yano T, Murata M, et al. Tumor-reactive T-cells accumulate in lung cancer tissues but fail to respond due to tumor cell-derived factor. Cancer Res 1992;52:775-81.
18. Woo EY, Yeh H, Chu CS, et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002; 168:4272-6.
19. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155: 1151-64.
20. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000;101:455-8.
21. Boon T, Cerottini J-C, Van den Eynde B, van der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994;12:337-65.
22. + T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999;163:5211-8.
23. Onizuka S, Tawara I, Shimizu J, et al. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody. Cancer Res 1999; 59:3128-33.
24. Sutmuller RP, van Duivenvoorde LM, van Elsas A, et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001;194: 823-32.
25. Sharma S, Stolina M, Zhu L, et al. Secondary lymphoid organ chemokine reduces pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res 2001;61:6406-12.
26. Kiertscher SM, Luo J, Dubinett SM, Roth MD. Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells. J Immunol 2000; 164:1269-76.
27. Magdaleno S, Wang G, Mireles V, et al. Cyclin-dependent kinase inhibitor expression in pulmonary Clara cells transformed with SV40 large T antigen in transgenic mice. Cell Growth Differ 1997;8:145-55.
28. Hillinger S, Yang SC, Zhu L, et al. EBV-induced molecule 1 ligand chemokine (ELC/CCL19) promotes IFN-γ-dependent antitumor responses in a lung cancer model. J Immunol 2003;171:6457-65.
29. 2 enhance peripheral blood lymphocyte IL-10 transcription and protein production. J Immunol 1996; 157:5512-20.
30. Sharma S, Yang SC, Hillinger S, et al. SLC/CCL21-mediated anti-tumor responses require IFNγ, MIG/CXCL9 and IP-10/CXCL10. Mol Cancer 2003;2:22.
31. Williams CS, Tsujii M, Reese J, Dey SK, DuBois RN. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000;105:1589-94.
32. 2. J Immunol 1994;153:1674.
33. Rohrer JW, Coggin JH Jr. CD8 T cell clones inhibit antitumor T cell function by secreting IL-10. J Immunol 1995;155:5719-27.
34. Khuri F, Wu H, Lee J, et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage 1 non-small cell lung cancer. Clin Cancer Res 2001;7:861-7.
35. Achiwa H, Yatabe Y, Hida T, et al. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 1999;5:1001-5.
36. Krysan K, Dalwadi H, Sharma S, Põld M, Dubinett S. Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer. Cancer Res 2004;64:6359-62.
37. Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-16.
38. 2 in cyclooxygenase-2 regulated, CD44-depedent invasion in non-small cell lung cancer. Proc Am Assoc Cancer Res 2002;43:371.
39. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(κ)B kinase-β. Nature 1998;396:77-80.
40. Janne PA, Mayer RJ. Chemoprevention of colorectal cancer. N Engl J Med 2000;342:1960-8.
41. Greten FR, Eckmann L, Greten TF, et al. IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004;118:285-96.
42. Pikarsky E, Porat RM, Stein I, et al. NF-κ functions as a tumour promoter in inflammation-associated cancer. Nature 2004;431:461-6. Epub 2004 Aug 25.
43. Wolf AM, Wolf D, Steurer M, et al. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003;9:606-12.
44. Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002;169:2756-61.
45. + regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 2003;98:1089-99.
46. Ichihara F, Kono K, Takahashi A, et al. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 2003;9:4404-8.
47. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299:1057-61.
48. + T regulatory cells. Nat Immunol 2003;4:337-42.
49. + regulatory T cells. Nat Immunol 2003;4:330-6.
50. Pold M, Krysan K, Pold A, et al. Cyclooxygenase-2 modulates the insulin-like growth factor axis in non-small-cell lung cancer. Cancer Res 2004;64:6549-55.
51. + T cells through Foxp3 induction and down-regulation of Smad7. J Immunol 2004;172:5149-53.
52. + regulatory T cell activity in both humans and mice. J Immunol 2004;172;834-42.